Resonance HealthASX:RHT +4.55% Quick Ratio is 1.87 as of Dec. 2025, which is 69% below its 10-year median of 5.98. The stock has 6 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Resonance Health ranks better than 65.89% on this metric.
Resonance Health has a quick ratio of 1.87. It generally indicates good short-term financial strength.
The historical rank and industry rank for Resonance Health's Quick Ratio or its related term are showing as below:
ASX:RHT'
s Quick Ratio Range Over the Past 10 Years
Min: 1.28 Med: 5.98 Max: 16.53
Current: 1.87
During the past 13 years, Resonance Health's highest Quick Ratio was 16.53. The lowest was 1.28. And the median was 5.98.
ASX:RHT's Quick Ratio is ranked better than 65.89% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 1.32
vs ASX:RHT: 1.87
Resonance Health (ASX:RHT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Resonance Health Quick Ratio Related Terms
Resonance Health Quick Ratio Historical Data
* Premium members only.
The historical data trend for Resonance Health's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, TEM: Quick Ratio Comparison
For the Health Information Services subindustry, Resonance Health's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Quick Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Resonance Health's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Resonance Health's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a Quick Ratio of 1.87 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Resonance Health and its competitors. This is 69% below median its historical median of 5.98. Over the past decade, Resonance Health's Quick Ratio has ranged from 1.28 to 16.53. According to the industry distribution chart, Resonance Health ranks #233 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 34.1%.
Is Resonance Health's Quick Ratio too high?
Resonance Health's current Quick Ratio of 1.87 is 69% below median its 10-year median of 5.98. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 16.53. The Healthcare Providers & Services industry median Quick Ratio is 1.32. Resonance Health's value of 1.87 is 41.7% above this industry median. Based on the distribution chart, Resonance Health ranks #233 out of 683 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Resonance Health's Quick Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #233 out of 683 companies for Quick Ratio. This puts Resonance Health in the upper half of its industry. The industry median Quick Ratio is 1.32. Resonance Health's value of 1.87 is 41.7% above this benchmark. Historically, Resonance Health's own Quick Ratio has ranged from 1.28 to 16.53 over the past decade. While the company's 10-year median is 5.98 vs. the industry median of 1.32, Resonance Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Healthcare Providers & Services company?
The median Quick Ratio among Healthcare Providers & Services companies is 1.32, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current Quick Ratio of 1.87 is 41.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median Quick Ratio is 1.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Quick Ratio is 1.87, which is 69% below median its own 10-year median of 5.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current Quick Ratio is 1.87, which is 69% below median its 10-year median of 5.98 and 41.7% above the Healthcare Providers & Services industry median of 1.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Quick Ratio is 1.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 